Evaluation Montelukast in the Treatment of Status Asthmaticus
The purpose of this study is to evaluate the effectiveness of oral montelukast (Singulair) given with other standard asthma medications and treatments in the treatment of children with status asthmaticus. Status asthmaticus is an acute asthma attack that does not respond to standard intermittent treatments but requires a continuous medication to aid in breathing. While new medications have been used to better manage chronic asthma, acute asthma exacerbations continue to be a significant cause of hospitalization and even death in children. Oral montelukast is a very safe medication that is used to manage chronic asthma in children, but it has not been studied for use in status asthmaticus. If oral montelukast, given with other standard therapies, can reduce the treatment length associated with severe, acute asthma exacerbations in children, it could potentially improve both the morbidity and burden of pediatric asthma.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
|Official Title:||A Prospective Analysis of the Use of Oral Montelukast in Children With Status Asthmaticus|
- Improvement of pediatric asthma score [ Time Frame: Hourly during the length of the patient's pediatric ICU hospitalization for status asthmaticus ] [ Designated as safety issue: No ]Measurement of pediatric asthma score hourly from admission assessing for time to improvement of score, an average length of stay predicted 2-4 days.
|Study Start Date:||January 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
Other Name: Singulair
Placebo Comparator: Placebo
One placebo capsule given every 24h
Gelatin capsule given every 24 hours
While new medications have been used to better manage chronic asthma, acute exacerbations continue to be a significant cause of pediatric morbidity and mortality. Montelukast holds an established role in the pediatric outpatient management of asthma and while two promising studies in adults have demonstrated its potential use as an adjunctive therapy for acute exacerbations, its similar use in pediatrics has yet to be established. This pilot study is designed as a prospective, double blinded, randomized, controlled, clinical trial comparing the use of oral montelukast plus standard of care vs. standard of care alone in children admitted for status asthmaticus to the pediatric intensive care unit (PICU). The primary outcome the investigators are interested in is the time to reach a Modified Pediatric Asthma Score (PAS) of < 5, which, per the clinical protocol for the treatment of status asthmaticus, is the time when patients are able to come off continuous bronchodilator therapy. If oral montelukast, given with other standard therapies, can reduce the treatment, emotional, and financial burden (e.g., shortened intensive care stay) associated with severe, acute asthma exacerbations in children, it would provide a significant therapeutic advantage, potentially improving both the morbidity and burden of pediatric asthma.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01770899
|Contact: Corrie E Fletcher, DOfirstname.lastname@example.org|
|Contact: Luis Torero, MD||708-684‑email@example.com|
|United States, Illinois|
|Advocate Children's Hospital Oak Lawn||Recruiting|
|Oak Lawn, Illinois, United States, 60453|
|Principal Investigator: Corrie Fletcher, DO|
|Principal Investigator:||Corrie Fletcher, DO||Advocate Health Care|